Globus Medical stock holds at Neutral as BTIG cites revenue miss

Globus Medical reported Q3 2026 revenue of $763.7 million, down 0.7% year over year and below the $792.4 million consensus, while adjusted EPS of $1.23 topped the $1.20 estimate. The company cut full-year revenue guidance to $3.09 billion, or 5.1% growth, from $3.18 billion–$3.22 billion, but reaffirmed adjusted EPS guidance of $4.95–$5.05. BTIG reiterated Neutral, while BMO downgraded the stock to Market Perform with a $78 price target.

Analysis

GMED | Revenue execution, not the EPS beat, is the near-term signal. Holding EPS guidance after lowering sales expectations suggests a margin or cost cushion, but it does not establish that the shortfall is temporary; verify the bridge through procedure volumes, mix, and operating expense. Strong Enabling Technology growth is a potential offset, yet it cannot be treated as proof of broad-based demand while legacy musculoskeletal growth has slowed and Nevro continues to contract. If launch delays persist, the risk is a longer period of weak growth and multiple pressure; competitors such as Medtronic, Stryker, and Zimmer Biomet may benefit if surgeons defer or redirect purchases, though the article provides no evidence of share shifts. The valuation claims in the source are not enough to establish a margin of safety without independently checking estimates and the growth assumptions embedded in them.

Over days, expect guidance credibility and the sales miss to outweigh the modest EPS beat. Over the next 1–3 months, monitor product-launch timing, procedure trends, and whether Nevro stabilizes. Over 6–18 months, the key question is whether Enabling Technology adoption can support durable growth and offset weakness elsewhere. The contrarian case is that launch timing, rather than structural demand, explains the slowdown; confirmation would require improving sales execution, not just reiterated EPS guidance.

Key Decisions for Investors

• Avoid adding to GMED on the EPS beat alone; treat the lowered revenue outlook and execution uncertainty as the dominant near-term setup.
• For an existing portfolio, consider a modest underweight versus a diversified medtech peer basket rather than an outright short. Reassess if launch delays extend or guidance is cut again; the article does not establish enough valuation or positioning data to size a high-conviction short.
• Watch the next quarterly update for launch milestones, underlying procedure growth, Nevro revenue stabilization, and the sales-to-EPS bridge. A further revenue shortfall or EPS guidance reduction would weaken the thesis; renewed organic growth and evidence of sustained technology adoption would falsify it.
• Do not rely on the cited PEG or fair-value characterization as a catalyst: independently verify the forecast inputs and whether the expected growth remains achievable.